Trial Profile
Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (Estrogen Receptor [ER] and/or Progesterone Receptor [PR] +) Human Epidermal Growth Factor Receptor 2 (HER-2) Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 19 Jun 2019 Status changed from completed to discontinued.
- 04 Apr 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2017).
- 12 Dec 2015 Status changed from active, no longer recruiting to completed according to results presented at the 38th Annual San Antonio Breast Cancer Symposium.